Liu Jinan, Emond Bruno, Maiese Eric M, Lafeuille Marie-Hélène, Lefebvre Patrick, Ghelerter Isabelle, Wu Caterina, Hurteau Jean A, Thaker Premal H
Value, Evidence, and Outcomes, GSK, Collegeville, PA, USA.
Analysis Group, Montreal, Quebec, Canada.
Curr Med Res Opin. 2022 Nov;38(11):1935-1945. doi: 10.1080/03007995.2022.2112872. Epub 2022 Aug 27.
Evaluate systemic therapy utilization patterns and outcomes by line of therapy among patients with advanced/recurrent endometrial cancer (EC) treated in the United States.
This retrospective observational study used the Optum Clinformatics Extended Data Mart Date of Death database (1 January 2004-31 December 2019) and included de-identified data from adult patients with advanced/recurrent EC who were treated with first-line (1L) platinum-based chemotherapy and initiated second-line (2L) anti-neoplastic therapy. The index date was the date of 1L therapy initiation. The number and sequence of treatments received and the proportion of patients who received each type of treatment for each line of therapy were evaluated. To account for new drug approvals, patients first treated in 2018 or 2019 were also assessed separately.
Among the 1317 patients who met all eligibility criteria, 520 (39.5%) and 235 (17.8%) patients received 3 or 4+ lines of treatment, respectively, during a median total follow-up time of 25.2 months (range, 2.5-173.3 months) following the index date. Chemotherapy, including platinum- and non-platinum-based regimens, was the most common treatment across all lines of therapy: 2L, 80.0%; 3L, 66.2%; 4L+, 80.4%. Overall, 2.5%, 2.3%, and 8.9% of 2L, 3L, and 4L + patients, respectively, received anti-program death 1 (anti-PD-1) immunotherapies. In patients first treated in 2018 and 2019 ( = 163), 9.8% of patients received anti-PD-1 immunotherapy in the 2L. In the overall population, median time to next treatment (TTNT) was 19.3, 10.5, and 8.1 months for patients undergoing 2L, 3L, and 4L treatment, respectively.
Among patients with advanced/recurrent EC treated with 1L platinum-based therapy in clinical practice, chemotherapy was the most common treatment choice across all lines of therapy. Immunotherapy use was low overall but increased in patients who started treatment in 2018 or 2019. Overall, median TTNT decreased as lines of therapy increased.
评估美国接受治疗的晚期/复发性子宫内膜癌（EC）患者按治疗线数划分的全身治疗使用模式及疗效。
这项回顾性观察研究使用了Optum临床信息学扩展数据集市死亡日期数据库（2004年1月1日至2019年12月31日），纳入了来自接受一线（1L）铂类化疗并开始二线（2L）抗肿瘤治疗的晚期/复发性EC成年患者的去识别数据。索引日期为1L治疗开始日期。评估了接受治疗的数量和顺序，以及每条治疗线接受每种治疗类型的患者比例。为考虑新药获批情况，对2018年或2019年首次接受治疗的患者也进行了单独评估。
在1317例符合所有纳入标准的患者中，在索引日期后的中位总随访时间25.2个月（范围2.5 - 173.3个月）内，分别有520例（39.5%）和235例（17.8%）患者接受了3线或4线以上治疗。化疗，包括铂类和非铂类方案，是所有治疗线中最常见的治疗方法：2L为80.0%；3L为66.2%；4L及以上为80.4%。总体而言，2L、3L和4L及以上患者分别有2.5%、2.3%和8.9%接受了抗程序性死亡1（抗PD - 1）免疫治疗。在2018年和2019年首次接受治疗的患者（n = 163）中，9.8%的患者在2L时接受了抗PD - 1免疫治疗。在总体人群中，接受2L、3L和4L治疗的患者下次治疗的中位时间（TTNT）分别为19.3个月、10.5个月和8.1个月。
在临床实践中接受1L铂类治疗的晚期/复发性EC患者中，化疗是所有治疗线中最常见的治疗选择。免疫治疗的总体使用率较低，但在2018年或2019年开始治疗的患者中有所增加。总体而言，随着治疗线数增加，中位TTNT缩短。
